Skip to content

EXTRAPHAR: what changed

BE 0788.510.921NACE 46.460, Wholesale of pharmaceutical and medical goodsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€29,296
2024 · -€35,630+€64,926
Equity
€234
2024 · -€29,062+€29,296
Cash
€5,127
2024 · €3,475+€1,652
Balance sheet total
€10,258
2024 · €14,874-€4,616

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€6,268

    down €6,268 (-55.0%), from €11,398 to €5,131

  • Cash +€1,652

    up €1,652 (+47.5%), from €3,475 to €5,127

    mainly Net result for the year (+€29,296) and Receivables within one year (+€6,268)

Equity and liabilities
  • Profit (loss) carried forward +€29,296

    up €29,296 (+92.8%), from -€31,562 to -€2,266

  • Trade debts -€17,515

    down €17,515 (-76.2%), from €22,995 to €5,480

  • Other debts -€15,516

    no longer reported in 2025 (was €15,516)

  • Tax, wage and social debts -€881

    down €881 (-16.2%), from €5,425 to €4,544

    of which Remuneration and social security: -€836

Income statement
  • Gross operating margin +€66,192

    up €66,192, from -€35,308 to €30,884

  • Taxes +€1,462

    new in 2025: €1,462

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 -€35,630
Gross operating margin +€66,192
Other operating charges +€159
Financial charges +€38
Taxes -€1,462
Result 2025 €29,296
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€1,652
Investment €0
Financing €0
Cash 2024 €3,475
Net result for the year +€29,296
Receivables within one year +€6,268
Trade debts -€17,515
Tax, wage and social debts -€881
Other debts -€15,516
Cash 2025 €5,127
brings cash intakes cash out
Every line side by side 28 lines
Line Code 2024 2025 Change %
Total assets 20/58 €14,874 €10,258 -€4,616 -31.0%
Current assets 29/58 €14,874 €10,258 -€4,616 -31.0%
Amounts receivable within one year 40/41 €11,398 €5,131 -€6,268 -55.0%
Trade receivables 40 €11,398 €5,131 -€6,268 -55.0%
Cash at bank and in hand 54/58 €3,475 €5,127 +€1,652 +47.5%
Total equity and liabilities 10/49 €14,874 €10,258 -€4,616 -31.0%
Equity 10/15 -€29,062 €234 +€29,296
Contributions 10/11 €2,500 €2,500 = 0.0%
Capital 10 €2,500 - -€2,500
Issued capital 100 €2,500 - -€2,500
Profit (loss) carried forward 14 -€31,562 -€2,266 +€29,296 +92.8%
Amounts payable 17/49 €43,936 €10,024 -€33,912 -77.2%
Amounts payable within one year 42/48 €43,936 €10,024 -€33,912 -77.2%
Trade debts 44 €22,995 €5,480 -€17,515 -76.2%
Suppliers 440/4 €22,995 €5,480 -€17,515 -76.2%
Taxes, remuneration and social security 45 €5,425 €4,544 -€881 -16.2%
Taxes 450/3 €4,589 €4,544 -€45 -1.0%
Remuneration and social security 454/9 €836 - -€836
Other amounts payable 47/48 €15,516 - -€15,516
Other operating charges 640/8 €159 - -€159
Gross operating margin 9900 -€35,308 €30,884 +€66,192
Operating profit (loss) 9901 -€35,467 €30,884 +€66,351
Financial charges 65/66B €163 €125 -€38 -23.1%
Recurring financial charges 65 €163 €125 -€38 -23.1%
Profit (loss) for the period before taxes 9903 -€35,630 €30,758 +€66,388
Income taxes 67/77 - €1,462 +€1,462
Profit (loss) for the period 9904 -€35,630 €29,296 +€64,926
Profit (loss) for the period to be appropriated 9905 -€35,630 €29,296 +€64,926

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€10,681 to €14,907

Midpoint €12,442 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Adjusted equity €234
Capitalised earnings €21,129 to €29,580
Indication €10,681 to €14,907

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€234
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€234

Capitalised earnings

net result for the year (9904)
2025
€29,296
2024
-€35,630
2023
€15,209
2022
-€11,142
Average result
€2,958
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€21,129 / €24,650 / €29,580

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 11 November 2026 via checked.be.